US SB4439 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 7-0)
Status: Introduced on August 5 2020 - 25% progression, died in committee
Action: 2020-08-05 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on August 5 2020 - 25% progression, died in committee
Action: 2020-08-05 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to require any COVID-19 drug developed in whole or in part with Federal support to be affordable and accessible by prohibiting monopolies and price gouging, and for other purposes.
Title
MMAPPP Act of 2020 Make Medications Affordable by Preventing Pandemic Price-gouging Act of 2020
Sponsors
| Sen. Tina Smith [D-MN] | Sen. Jeff Merkley [D-OR] | Sen. Tammy Baldwin [D-WI] | Sen. Kirsten Gillibrand [D-NY] |
| Sen. Kamala Harris [D-CA] | Sen. Cory Booker [D-NJ] | Sen. Christopher Murphy [D-CT] |
History
| Date | Chamber | Action |
|---|---|---|
| 2020-08-05 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB7296 (Related) 2020-06-22 - Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Subjects
Business records
Cardiovascular and respiratory health
Civil actions and liability
Corporate finance and management
Drug safety, medical device, and laboratory regulation
Emergency medical services and trauma care
Government information and archives
Health
Health programs administration and funding
Health promotion and preventive care
Immunology and vaccination
Infectious and parasitic diseases
Inflation and prices
Intellectual property
Licensing and registrations
Manufacturing
Medical research
Medical tests and diagnostic methods
Performance measurement
Prescription drugs
Research administration and funding
Research and development
User charges and fees
Wages and earnings
Cardiovascular and respiratory health
Civil actions and liability
Corporate finance and management
Drug safety, medical device, and laboratory regulation
Emergency medical services and trauma care
Government information and archives
Health
Health programs administration and funding
Health promotion and preventive care
Immunology and vaccination
Infectious and parasitic diseases
Inflation and prices
Intellectual property
Licensing and registrations
Manufacturing
Medical research
Medical tests and diagnostic methods
Performance measurement
Prescription drugs
Research administration and funding
Research and development
User charges and fees
Wages and earnings
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/senate-bill/4439/all-info |
| Text | https://www.congress.gov/116/bills/s4439/BILLS-116s4439is.pdf |
